Citius Pharmaceuticals, Inc.

CTXRSEC EDGAR

Pharmaceutical Preparations(NV)CIK: 1506251

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	—	—	—	—	—
Cost of Goods and Services Sold	—	—	—	—	—
Research and Development Expense	$11.9M	$14.8M	$17.7M	$12.2M	$8.8M
Operating Expenses	$42.0M	$36.7M	$33.3M	$23.5M	$17.7M
Operating Income (Loss)	-$42.0M	-$36.7M	-$33.3M	-$23.5M	-$17.7M
Interest Expense	—	—	—	$10.8K	$15.7K
Nonoperating Income (Expense)	$3.1M	$4.8M	$251.4K	—	$162.6K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$116.7M	$103.6M	$114.0M	$142.4M	$43.8M
Assets, Current	$14.2M	$34.4M	$44.6M	$72.8M	$14.0M
Cash and Cash Equivalents, at Carrying Value	$3.3M	$26.5M	$41.7M	$70.1M	$7.9M
Inventory, Net	$8.3M	—	—	—	—
Liabilities	$42.5M	$12.2M	$10.6M	$9.6M	$10.1M
Liabilities, Current	$35.8M	$5.8M	$4.5M	$4.0M	$4.1M
Accounts Payable, Current	$4.9M	$2.9M	$1.2M	$1.3M	$1.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$28.2M	-$29.1M	-$28.4M	-$24.3M	-$16.9M
Net Cash Provided by (Used in) Investing Activities	-$5.0M	-$5.0M	—	-$40.0M	-$1.8K
Net Cash Provided by (Used in) Financing Activities	$10.0M	$13.8M	$13.8M	$120.5M	$22.9M
Payments to Acquire Property, Plant, and Equipment	—	—	—	$6.9K	$1.8K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)